
Please try another search
(Reuters) - Gilead Sciences Inc (NASDAQ:GILD) said on Tuesday it would buy a 49.9% stake in privately held cancer immunotherapies developer Pionyr Immunotherapeutics Inc for $275 million.
The drugmaker said it has also secured the right to acquire the rest of Pionyr for a $315 million option exercise fee.
Pionyr's immuno-oncology product candidates, PY314 and PY159, have shown potential against solid tumors in animal studies and it plans to file applications with the U.S. Food and Drug Administration in the third quarter to begin human testing.
Gilead has been expanding its oncology portfolio. In March, the company announced a $4.9 billion deal for Forty Seven Inc, adding an experimental treatment that targets blood cancer.
The deal comes as Gilead is racing to expand the global supply of its antiviral drug remdesivir for use in COVID-19, a respiratory illness that has no currently approved treatments or vaccines.
Pionyr's shareholders are also eligible to receive up to an additional $1.47 billion in option exercise fees and future milestone payments.
(Reuters) - Scandinavian airline SAS said on Saturday it entered into an agreement with Apollo Global Management (NYSE:APO) to raise $700 million of fresh financing it needs to...
(Reuters) -Anshu Jain, a top finance executive best known for helping German lender Deutsche Bank AG (NYSE:DB) take on the largest Wall Street firms, died overnight on Saturday...
By Svea Herbst-Bayliss (Reuters) - The New York Times Co has turned to Bank of America Corp (NYSE:BAC) and law firm Sidley Austin LLP for advice on how to handle a potential board...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.